RNA targeting and collaboration platform for siRNA partnerships including the AbbVie license agreement.

ADARx Pharmaceuticals: Pioneering in mRNA base editing for genetic medicine solutions.
Founded with a mission to transform cutting-edge science into life-saving therapeutics, ADARx Pharmaceuticals is a pioneering genetic medicine company specializing in mRNA base editing. The company focuses on developing a modality-agnostic RNA targeting platform, which includes oligonucleotides for inhibition, degradation, and editing, along with innovative delivery technologies. ADARx aims to address intractable diseases across three primary therapeutic areas, leveraging its multi-faceted RNA targeting platform for wide-ranging therapeutic interventions.
ADARx Pharmaceuticals has attracted notable investors and industry experts who support its groundbreaking work in genetic medicine. The company has achieved significant milestones in advancing its drug platform and building a deep pipeline of potential therapeutics. Its impact is evident in the innovative approaches it brings to the field of genetic medicine, offering new hope for treating previously untreatable conditions through precise mRNA targeting and editing.

Creyon Bio
creyonbio.com

Ionis Pharmaceuticals
ionispharma.com

Korro Bio
korrobio.com

Shape Therapeutics
shapetx.com

Ascidian Therapeutics
ascidian-tx.com

ReNAgade Therapeutics
renagadetx.com

Wave Life Sciences

ReviR Therapeutics
revirtx.com

Avidity Biosciences
aviditybio.com

Arrakis Therapeutics
arrakistx.com

Arvinas
arvinas.com

Arcturus Therapeutics Holdings
arcturusrx.com

Alltrna
alltrna.com

Rnaimmune
rnaimmune.com

Adrx
adrxpharma.com
Companies similar to Adarx Pharmaceuticals include Creyon Bio, Ionis Pharmaceuticals, Korro Bio and Shape Therapeutics.
Adarx Pharmaceuticals was founded in 2019.
Adarx Pharmaceuticals' headquarters is located in San Diego, CA, US.
Adarx Pharmaceuticals' most recent funding round was for $200M (USD) in August 2023.
As of Aug 9, 2023, Adarx Pharmaceuticals has disclosed funding of $332M (USD). Undisclosed round amounts are excluded.
Adarx Pharmaceuticals has 50 employees as of Feb 5, 2024.